MedTrace Logo

Dehydroepiandrosterone Maintain Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders

NCT03438812 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-02-18

No results posted yet for this study

Summary

To investigate whether the DHEA supplementation could improve mitochondrial quality in poor ovarian responders

Conditions

  • Poor Responders
  • Dehydroepiandrosterone

Interventions

DIETARY_SUPPLEMENT

dehydroepiandrosterone (DHEA)

Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.

Sponsors & Collaborators

  • Kaohsiung Veterans General Hospital.

    lead OTHER

Principal Investigators

  • Kuan-Hao Tsui, Ph.D. · Kaohsiung Veterans General Hospital.

  • Li-Te Lin, Ph.D. · Kaohsiung Veterans General Hospital.

  • Salvatore Giovanni Vitale, M.D. · University of Messina

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-06
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03438812 on ClinicalTrials.gov